Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway

Oncotarget

Volumn 6, Issue 9, 2015, Pages 6627-6640

  Cao, Lei ^a,b,e   Fan, Xiaoyu ^b   Jing, Wei ^c   Liang, Yingchao ^b   Chen, Rui ^b   Liu, Yingying ^b,c   Zhu, Minhui ^c   Jia, Rongjie ^b   Wang, Hao ^b   Zhang, Xueguang ^e   Zhang, Yanyun ^a   Zhou, Xuyu ^c   Zhao, Jian ^b,d,f   Guo, Yajun ^b,d,f  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^f PEKING UNIVERSITY   (China)

Author keywords

Cancer stem cell; Hepatocellular carcinoma; Osteopontin; Stemness

Indexed keywords

BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; FLUOROURACIL; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOPONTIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; BMI1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; ITGB3 PROTEIN, HUMAN; SPP1 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BMI1 GENE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL VIABILITY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CHEMORESISTANT CANCER CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HIF 1 ALPHA GENE; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OCT4 GENE; OVERALL SURVIVAL; PHENOTYPE; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SELF RENEWAL CAPACITY; SURVIVAL TIME; TUMOR SPHEROID; UPREGULATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; NEOPLASTIC STEM CELLS; NF-KAPPA B; OSTEOPONTIN; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 1; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSFECTION;

EID: 84927145212     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3113     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62:10-29.
2. Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M. Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant. 2006; 4:549-558.
3. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocel-lular carcinoma. Semin Oncol. 2001; 28:503-513.
4. Llovet JM, Bruix J. Systematic review of random-ized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37:429-442.
5. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8:755-768.
6. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. Tie2/angiopoietin-1 signaling regu-lates hematopoietic stem cell quiescence in the bone mar-row niche. Cell. 2004; 118:149-161.
7. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10:8152-8162.
8. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, Barnard GF, Doki Y, Mori M. CD13 is a therapeutic tar-get in human liver cancer stem cells. J Clin Invest. 2010; 120:3326-3339.
9. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by pref-erential expression of the Akt/PKB survival pathway. Oncogene. 2008; 27:1749-1758.
10. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, Zheng BJ, Lai PB, Lo CM, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010; 7:694-707.
11. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008; 13:153-166.
12. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell fea-tures. Gastroenterology. 2009; 136:1012-1024.
13. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regula-tion. Cell Stem Cell. 2011; 9:50-63.
14. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006; 44:240-251.
15. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004; 90:1877-1881.
16. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16:79-87.
17. Zhao J, Dong L, Liu B, Wu GB, Xu DM, Chen JJ, Li K, Tong X, Dai JX, Yao S, Wu MC, Guo YJ. Down-regulation of osteopontin suppresses growth and metasta-sis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008; 135:956-968.
18. Wai PY, Mi Z, Gao C, Guo H, Marroquin C, Kuo PC. Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem. 2006; 281:18973-18982.
19. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stim-ulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem. 2003; 278:28593-28606.
20. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2004; 279:38921-38935.
21. Rangaswami H, Bulbule A, Kundu GC. JNK1 differen-tially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2005; 280:19381-19392.
22. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005; 201:1781-1791.
23. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ, Haylock DN. Osteopontin, a key compo-nent of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005; 106:1232-1239.
24. Pietras A, Katz AM, Ekstrom EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014; 14:357-369.
25. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006; 24:506-513.
26. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and can-cer stem cell research. Cell Stem Cell. 2011; 8:136-147.
27. Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, Liao Y, Wu WZ, Ji Y, Ke AW, Ding ZB, He YZ, Wu B, et al. Identification of side population cells in human hepatocellu-lar carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol. 2008; 134:1155-1163.
28. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propaga-tion and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17:1253-1270.
29. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH, Jeong SH. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006; 101:2051-2059.
30. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK, Wu KJ. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol. 2010; 12:982-992.
31. Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Gorlach A. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 2007; 27:755-761.
32. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014; 64:9-29.
33. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis pro-gression in nonalcoholic steatohepatitis. Hepatology. 2011; 53:106-115.
34. Wang X, Lopategi A, Ge X, Lu Y, Kitamura N, Urtasun R, Leung TM, Fiel MI, Nieto N. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014.
35. Rao G, Wang H, Li B, Huang L, Xue D, Wang X, Jin H, Wang J, Zhu Y, Lu Y, Du L, Chen Q. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res. 2013; 19:785-797.
36. Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC. Osteopontin signaling upregulates cyclooxy-genase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Oncogene. 2014; 33:2295-2306.
37. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells-perspectives on current status and future direc-tions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66:9339-9344.
38. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A temporarily distinct sub-population of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010; 141:583-594.
39. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2006; 20:385-391.
40. Blagosklonny MV. Cancer stem cell and cancer stem-loids: from biology to therapy. Cancer Biol Ther. 2007; 6:1684-1690.
41. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumori-genic capacity of glioma stem cells. Cancer Cell. 2009; 15:501-513.
42. Cantilena S, Pastorino F, Pezzolo A, Chayka O, Pistoia V, Ponzoni M, Sala A. Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuro-blastomas. Oncotarget. 2011; 2:976-983.
43. Shareef MM, Udayakumar TS, Sinha VK, Saleem SM, Griggs WW. Interaction of HIF-1alpha and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells. Genes Cancer. 2013; 4:513-523.
44. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011; 8:399-411.
45. Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S, Kundu GC. Hypoxia-driven osteopon-tin contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent angiogenesis. Oncogene. 2014; 33:2053-2064.
46. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene. 2014; 33:1297-1305.